Designer natriuretic peptides

Journal of Investigative Medicine

Volumn 57, Issue 1, 2009, Pages 18-21

  Lee, Candace Y W ^a   Lieu, Hsiao ^b   Burnett Jr , John C ^a  

^a MAYO CLINIC   (United States)

^b Nile Therapeutics   (United States)

Author keywords

Hybrid peptides; Natriuretic peptide; Renal function

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; C TERMINUS OF DENDROAPSIS NATRIURETIC PEPTIDE; DENDROAPSIS NATRIURETIC PEPTIDE; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE TYPE C; UNCLASSIFIED DRUG; URODILATIN; VASONATRIN; CHIMERIC PROTEIN; VASONATRIN NATRIURETIC PEPTIDE;

ACUTE CORONARY SYNDROME; CONFERENCE PAPER; CONTINUOUS INFUSION; DRUG BINDING; DRUG DOSE ESCALATION; HEART FAILURE; HUMAN; HYPERTENSION; HYPOTENSION; ISCHEMIC HEART DISEASE; LABORATORY; METABOLIC DISORDER; NATRIURESIS; NEOPLASM; NONHUMAN; ORTHOSTATIC HYPOTENSION; VASCULAR DISEASE; VASODILATATION; DRUG DESIGN; REVIEW; ANTIPROLIFERATIVE ACTIVITY; CARBOXY TERMINAL SEQUENCE; DIURESIS; ENDOTHELIUM CELL; GLOMERULUS FILTRATION RATE; HEART FIBROBLAST; HEART RIGHT ATRIUM PRESSURE; IN VITRO STUDY; MEAN ARTERIAL PRESSURE; PROTEIN ANALYSIS; PROTEIN ENGINEERING; SECOND MESSENGER;

DRUG DESIGN; HUMANS; NATRIURETIC PEPTIDES;

EID: 85047682000     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.2310/JIM.0b013e3181946fb2     Document Type: Conference Paper

References (51)

1. Wei CM, Kim CH, Miller VM, et al. Vasonatrin peptide: a unique synthetic natriuretic and vasorelaxing peptide. J Clin Invest. 1993;92:2048-2052.
2. de Bold AJ, Borenstein HB, Veress AT, et al. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci. 1981;28:89-94.
3. Sudoh T, Kangawa K, Minamino N, et al. A new natriuretic peptide in porcine brain. Nature. 1988;332:78-81.
4. Sudoh T, Minamino N, Kangawa K, et al. C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain. Biochem Biophys Res Commun. 1990;168:863-870.
5. Schulz-Knappe P, Forssmann K, Herbst F, et al. Isolation and structural analysis of "urodilatin," a new peptide of the cardiodilatin-(ANP)- family, extracted from human urine. Klin Wochenschr. 1988;66:752-759.
6. Schweitz H, Vigne P, Moinier D, et al. A new member of the natriuretic peptide family is present in the venom of the green mamba (Dendroaspis angusticeps). J Biol Chem. 1992;267:13928-13932.
7. Lisy O, Jougasaki M, Heublein D, et al. Renal actions of synthetic Dendroaspis natriuretic peptide. Kidney Int. 1999;56:502-508.
8. Lisy O, Lainchbury JG, Leskinen H, et al. Therapeutic actions of a new synthetic vasoactive and natriuretic peptide, Dendroaspis natriuretic peptide, in experimental severe congestive heart failure. Hypertension. 2001;37:1089-1094.
9. Best PJ, Burnett JC, Wilson SH, et al. Dendroaspis natriuretic peptide relaxes isolated human arteries and veins. Cardiovasc Res. 2002;55:375-384.
10. Koller KJ, Lowe D, Bennett G, et al. Selective activation of the B natriuretic peptide receptor by C-type natriuretic peptide (CNP). Science. 1991;252:120-123.
11. Suga S, Nakao K, Hosoda K, et al. Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide. Endocrinology. 1992;130:229-239.
12. Singh G, Kuc RE, Maguire JJ, et al. Novel snake venom ligand Dendroaspis natriuretic peptide is selective for natriuretic peptide receptor-A in human heart: downregulation of natriuretic peptide receptor-A in heart failure. Circ Res. 2006;99:183-190.
13. Lee CYW, Burnett JC Jr. Natriuretic peptides and therapeutic applications. Heart Fail Rev. 2007;12:131-142.
14. Wei CM, Kim CH, Khraibi AA, et al. Atrial natriuretic peptide and C-type natriuretic peptide in spontaneously hypertensive rats and their vasorelaxing actions in vitro. Hypertension. 1994;23:903-907.
15. Woodard GE, Li X, Brown J, et al. Receptor subtypes for vasonatrin peptide in renal glomeruli and arteries [published correction appears in Regul Pept 2008;2147(2001-2003):2110]. Regul Pept. 2005;129:183-189.
16. Feng HS, Zhang Z, Zhu X, et al. Comparison of vasorelaxing actions of vasonatrin peptide, C-type natriuretic peptide and atrial natriuretic peptide (translated from Chinese). Sheng Li Xue Bao. 1999;51:515-520.
17. Yu J, Zhe X, Wei G, et al. Vasorelaxing role of vasonatrin peptide in human intramammary artery invitro (translated from Chinese). Sheng Li Xue Bao. 2003;55:187-190.
18. Lu SY, Zhu MZ, Guo HT, et al. Inhibition of moderate hypoxia-induced protein synthesis by vasonatrin peptide in cultured neonatal rat cardiomyocytes (translated from Chinese). Sheng Li Xue Bao. 2002; 54:7-11.
19. Dong MQ, Zhu MZ, Yu J, et al. Comparison of inhibitory effects of three natriuretic peptides on the proliferation of pulmonary artery smooth muscle cells of rats (translated from Chinese). Sheng Li Xue Bao. 2000;52:252-254.
20. Lisy O, Huntley BK, McCormick DJ, et al. Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. J Am Coll Cardiol. 2008;52:60-68.
21. Suwa M, Seino Y, Nomachi Y, et al. Multicenter prospective investigation on efficacy and safety of carperitide for acute heart failure in the 'real world' of therapy. Circ J. 2005;69:283-290.
22. Publication Committee for the VMAC Investigators (Vasodilation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial [published correction appears in JAMA 2002;1288:1577]. JAMA. 2002;287:1531-1540.
23. Mitrovic V, et al. Haemodynamic and clinical effects of ularitide in decompensated heart failure. Eur Heart J. 2006;27:2823-2832.
24. Dorner GT, Selenko N, Kral T, et al. Hemodynamic effects of continuous urodilatin infusion: a dose-finding study. Clin Pharmacol Ther. 1998;64:322-330.
25. Wei CM, Aarhus LL, Miller VM, et al. Action of C-type natriuretic peptide in isolated canine arteries and veins. Am J Physiol. 1993; 264:H71-H73.
26. Burnett JC Jr, Opgenorth TJ, Granger JP. The renal action of atrial natriuretic peptide during control of glomerular filtration. Kidney Int. 1986;30:16-19.
27. Burnett JC Jr, Korinek J. The tumultuous journey of nesiritide: past, present, and future. Circ Heart Fail. 2008;1:6-8.
28. Soeki T, Kishimoto I, Okumura H, et al. C-type natriuretic peptide, a novel antifibrotic and antihypertrophic agent, prevents cardiac remodeling after myocardial infarction. J Am Coll Cardiol. 2005;45: 608-616.
29. Clavell AL, Stingo AJ, Wei CM, et al. C-type natriuretic peptide: a selective cardiovascular peptide. Am J Physiol. 1993;264:R290-295.
30. Lisy O, Burnett JC Jr. The design, synthesis and cardiorenal actions of a new chimeric natriuretic peptide CD-NP [abstract]. J Am Coll Cardiol. 2003;41:312A.
31. Lee CY, Boerrigter G, Harty GJ, et al. Pharmacodynamic profile of a novel chimeric natriuretic peptide, CD-NP, as compared to C-type natriuretic peptide [abstract]. Circulation. 2007;116(suppl II):II-550.
32. Lisy O, Huntley BK, McCormick DJ, et al. Design, synthesis and unique biological actions of CD-NP: a novel CNP-like chimeric natriuretic peptide [abstract]. Circulation. 2006;114:II-440.
33. Lee CY, Sandberg SM, Chen HH, et al. Renal cyclic GMP stimulating actions of a novel chimeric natriuretic peptide CD-NP in isolated glomeruli: evidence for NPR-A activation [abstract]. J Card Fail. 2008;14:S11.
34. Huntley BK, Burnett JJC. Anti-proliferative mechanisms of BNP in cultured human cardiac fibroblasts: role for the clearance receptor, p21 and cyclin D1 [abstract]. J Card Fail. 2006;12:S43.
35. Lee CYW, Chen H, Lieu H, et al. A phase I clinical trial on a novel chimeric natriuretic peptide, CD-NP [abstract]. J Am Coll Cardiol. 2008;51:A324.
36. Letts G, Loscalzo J. Frontiers in nephrology: targeting inflammation using novel nitric oxide donors. J Am Soc Nephrol. 2007;18:2863-2869.
37. Mills RM, LeJemtel T, Horton D, et al. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. J Am Coll Cardiol. 1999;34:155-162.
38. Kitakaze M, Asakura M, Kim J, et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet. 2007; 370:1483-1493.
39. Hillock RJ, Frampton C, Yandle T, et al. B-type natriuretic peptide infusions in acute myocardial infarction. Heart. 2008;94:617-622.
40. Kasama S, Furuya M, Toyama T, et al. Effects of intravenous atrial natriuretic peptide on cardiac sympathetic nerve activity and left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol. 2007;49:667-674.
41. Chen H, Schirger J, Lerman A, et al. Intravenous BNP at the time of acute anterior myocardial infarction in humans improves left ventricular remodeling [abstract]. Circulation. 2005.
42. Park K, Itoh H, Yamahara K, et al. Therapeutic potential of atrial natriuretic peptide administration on peripheral arterial diseases. Endocrinology. 2008;149:483-491.
43. Chen HH, Redfield MM, Nordstrom LJ, et al. Subcutaneous administration of the cardiac hormone BNP in symptomatic human heart failure. J Card Fail. 2004;10:115-119.
44. Cataliotti A, Shirger J, Martin F, et al. Oral human brain natriuretic peptide activates cyclic guanosine 3′,5′-monophosphate and decreases mean arterial pressure. Circulation. 2005;112:836-840.
45. Cataliotti A, James K, Chen HH, et al. Chronic actions of a novel oral B-type natriuretic peptide conjugate in normal dogs and acute actions in angiotensin II-mediated hypertension. Circulation. 2008;118: 1729-1736.
46. Sengenes C, Berlan M, De Glisezinski I, et al. Natriuretic peptides: a new lipolytic pathway in human adipocytes. FASEB J. 2000;14:1345-1351.
47. Meirhaeghe A, Sandu M, McCarthy M, et al. Association between the T-381C polymorphism of the brain natriuretic peptide gene and risk of type 2 diabetes in human populations. Hum Mol Genet. 2007;16: 1343-1350.
48. Vesely BA, McAfee Q, Gower WR Jr, et al. Four peptides decrease the number of human pancreatic adenocarcinoma cells. Eur J Clin Invest. 2003;33:998-1005.
49. Vesely DL. Atrial natriuretic peptides: anticancer agents. J Investig Med. 2005;53:360-365.
50. Vesely DL, Song S, Sanchez-Ramos J, et al. Four peptide hormones decrease the number of human breast adenocarcinoma cells. Eur J Clin Invest. 2005;35:60-69.
51. Cataliotti A, Chen HH, James KD, et al. Oral brain natriuretic peptide: a novel strategy for chronic protein therapy for cardiovascular disease. Trends Cardiovasc Med. 2007;17:10-14.